Discovery on Target 2026 has ended. This guide stays up as the record of who was there. Next: Discovery on Target 2027, Oct 18–21, 2027 in Boston

Biotech companies at Discovery on Target 2026

Sep 28 – Oct 1, 2026 Boston, MA ~1.1k attendees Website

170 biotech companies are at Discovery on Target 2026 — 139 presentations on the program. Most represented: Foghorn Therapeutics (3 on the program), Revolution Medicines (3 on the program), Frontier Medicines (2 on the program). 40 of them have their own page in this guide. As of Oct 8, 2026.

All 510 organizations at Discovery on Target 2026 →

Showing 1–11 of 170 organizations

Organization	Discovery on Target 2026 Attendance
Foghorn Therapeutics Cambridge, MA
foghorntx.com Biotech Clinical-stage biotech targeting the chromatin regulatory system with small molecules and protein degraders for cancer.	Panel Mon Sep 28 10:45am–11:30am Implementation of Computational Strategies for Driving Proximity-Induced Therapies Symposium: Induced Proximity-Based Drug Discovery · with Barcelona Supercomputing Center, InduPro, Novartis Talk Mon Sep 28 3:05pm–3:35pm Rewiring Transcription via Induced Proximity Symposium: Induced Proximity-Based Drug Discovery Chair Tue Sep 29 1:45pm–1:50pm Chairperson's Remarks Novel Drug Modalities Talk Thu Oct 1 9:05am–9:25am First-in-Class ARID1B Degraders Enable Targeting of ARID1A-Mutant Cancers Novel Drug Modalities
Revolution Medicines Redwood City, CA
revmed.com Biotech Oncology company developing oral RAS(ON) inhibitors for RAS-driven cancers.	Talk Tue Sep 29 9:05am–9:35am Zoldonrasib, an Oral, RAS(ON) G12D-Selective, Covalent, Tri-Complex Inhibitor Lead Generation Strategies Talk Tue Sep 29 9:35am–10:05am Discovery of Diverse RAS(ON) Inhibitor Profiles by Chemically Remodeling a Cellular Chaperone Novel Drug Modalities Panel Wed Sep 30 5:50pm–6:30pm Connect the DOTS for Start-Ups & Funding Plenary · with Nova Rain Capital, Ilerabio Panel Thu Oct 1 7:30am–8:15am Setting Up Collaborations & Partnerships Plenary · with Johnson & Johnson
Frontier Medicines
frontiermeds.com Biotech Biotech combining chemoproteomics, covalent chemistry and machine learning to drug hard-to-target proteins in cancer and immunology.	Chair Mon Sep 28 9:10am–9:15am Chairperson's Remarks Symposium: Induced Proximity-Based Drug Discovery Chair Tue Sep 29 8:30am–8:35am Chairperson's Remarks Lead Generation Strategies Talk Tue Sep 29 11:35am–12:05pm Breaking In: How Covalent AI Is Picking the Lock on Undruggable Proteins Innovative Discovery Technologies Panel Wed Sep 30 4:50pm–5:50pm Venture-Capitalist Insights on Trends in Drug Discovery Plenary · with Curie.Bio, General Inception, Lilly Asia Ventures +3 more
Dewpoint Therapeutics Boston, MA
dewpointx.com Biotech Biotech developing drugs that act on biomolecular condensates.	Talk Tue Sep 29 9:05am–9:35am Therapeutic Targeting of Disease-Associated Biomolecular Condensates Novel Drug Modalities Panel Thu Oct 1 7:30am–8:15am Emergence of New Modalities & Their Likelihood of Clinical Success Novel Drug Modalities · with Harvard Medical School, Tahoe Therapeutics
KT Kainova Therapeutics
	Talk Tue Sep 29 8:35am–9:05am Development and Comprehensive Characterization of DT-7012, a Highly Differentiated Anti-CCR8-Depleting Antibody in Immuno-Oncology Antibodies Against Challenging Targets Talk Wed Sep 30 12:20pm–12:50pm MC4R-BAPC: Revisiting an Old Target for Obesity Lead Generation Strategies
Mariana Oncology
marianaoncology.com Biotech Radioligand therapy developer for cancer, acquired by Novartis in 2024.	Talk Tue Sep 29 8:35am–9:05am Discovery of a DLL3-Targeting Macrocyclic Peptide Radioligand Therapy for the Treatment of SCLC Radioligand Therapies Panel Wed Sep 30 3:05pm–4:05pm From Target to Therapy: Science, Strategy, and Scalability Radioligand Therapies · with Perceptive, Curium, AstraZeneca +1 more
Montai Therapeutics
montai.com Biotech Develops oral medicines for chronic inflammatory diseases using AI and natural chemistry.	Panel Wed Sep 30 4:50pm–5:50pm Venture-Capitalist Insights on Trends in Drug Discovery Plenary · with Frontier Medicines, Curie.Bio, General Inception +3 more Panel Thu Oct 1 7:30am–8:15am Scientific Work in the Age of AI Agents Innovative Discovery Technologies · with University of Michigan, bPrescient
Normunity New Haven, Connecticut
	Chair Tue Sep 29 8:30am–8:35am Chairperson's Remarks Radioligand Therapies Panel Tue Sep 29 11:05am–12:05pm Defining Next-Generation Radioligand Therapies: From Molecular Design to Clinical and Commercial Success Radioligand Therapies · with Lumina Pharmaceuticals, Ratio Therapeutics, Perspective Therapeutics +2 more Chair Tue Sep 29 1:45pm–1:50pm Chairperson's Remarks Radioligand Therapies Talk Tue Sep 29 3:35pm–3:50pm Q&A with the Speakers Radioligand Therapies
Tahoe Therapeutics South San Francisco, CA
tahoebio.ai Biotech Generates large single-cell perturbation datasets and trains AI models that predict how cells respond to drugs.	Panel Thu Oct 1 7:30am–8:15am Emergence of New Modalities & Their Likelihood of Clinical Success Novel Drug Modalities · with Dewpoint Therapeutics, Harvard Medical School Panel Thu Oct 1 2:25pm–3:20pm Starting Up: Translating Lab Ideas into Commercial Impact Plenary · with Portal Biotechnologies, Massachusetts Institute of Technology, Kiral Medicines +3 more Chair Thu Oct 1 3:30pm–3:35pm Chairperson's Remarks Innovative Discovery Technologies Talk Thu Oct 1 3:35pm–4:05pm Billion-Cell Perturbational Datasets: Building, Integrating, and Translating Unified Atlases into Drug Discovery Innovative Discovery Technologies
Aureka Biotechnologies
aurekabio.com Biotech AI-driven start-up discovering antibody therapeutics, including GPCR modulators, for cardiometabolic and inflammatory diseases.	Chair Tue Sep 29 1:45pm–1:50pm Chairperson’s Remarks Antibodies Against Challenging Targets Talk Tue Sep 29 2:20pm–2:50pm Engineering Function: AI-Designed Antibodies that Modulate GPCRs Antibodies Against Challenging Targets Panel Wed Sep 30 7:30am–8:15am The Future of Functional Biologics: How AI is Changing Target Discovery, Design, and Therapeutic Modulation Antibodies Against Challenging Targets
KM Kiral Medicines
	Panel Thu Oct 1 2:25pm–3:20pm Starting Up: Translating Lab Ideas into Commercial Impact Plenary · with Portal Biotechnologies, Massachusetts Institute of Technology, AIRNA +3 more Chair Thu Oct 1 3:30pm–3:35pm Chairperson's Remarks Novel Drug Modalities Talk Thu Oct 1 4:35pm–5:05pm Modality Optionality: Expanding Druggability, Pushing the Limits of Chemical Space Novel Drug Modalities